Which has higher valuation and earnings, ANNX or ALMS?

Annexon has higher earnings, but lower revenue than Alumis. Alumis is trading at a lower price-to-earnings ratio than Annexon, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Annexon N/A N/A -$206.69M -$1.22 N/A Alumis $24.05M 148.96 -$243.32M -$1.98 N/A

Is ANNX or ALMS more profitable?

Annexon has a net margin of 0.00% compared to Alumis' net margin of -2,825.70%. Alumis' return on equity of -88.79% beat Annexon's return on equity. Company Net Margins Return on Equity Return on Assets Annexon N/A -101.19% -75.99% Alumis -2,825.70% -88.79% -70.72%

Does the media prefer ANNX or ALMS?

In the previous week, Alumis had 2 more articles in the media than Annexon. MarketBeat recorded 6 mentions for Alumis and 4 mentions for Annexon. Annexon's average media sentiment score of 0.52 beat Alumis' score of 0.44 indicating that Annexon is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Annexon 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alumis 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to CPRX or ANNX?

In the previous week, Annexon had 1 more articles in the media than Catalyst Pharmaceuticals. MarketBeat recorded 4 mentions for Annexon and 3 mentions for Catalyst Pharmaceuticals. Catalyst Pharmaceuticals' average media sentiment score of 1.49 beat Annexon's score of 0.52 indicating that Catalyst Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Catalyst Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Annexon 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is ANNX or RCUS more profitable?

Annexon has a net margin of 0.00% compared to Arcus Biosciences' net margin of -156.36%. Arcus Biosciences' return on equity of -68.97% beat Annexon's return on equity. Company Net Margins Return on Equity Return on Assets Annexon N/A -101.19% -75.99% Arcus Biosciences -156.36% -68.97% -35.27%

Does the media favor ANNX or RCUS?

In the previous week, Arcus Biosciences had 5 more articles in the media than Annexon. MarketBeat recorded 9 mentions for Arcus Biosciences and 4 mentions for Annexon. Arcus Biosciences' average media sentiment score of 1.15 beat Annexon's score of 0.52 indicating that Arcus Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Annexon 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Arcus Biosciences 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is ANNX or BEAM more profitable?

Annexon has a net margin of 0.00% compared to Beam Therapeutics' net margin of -39.66%. Beam Therapeutics' return on equity of -29.00% beat Annexon's return on equity. Company Net Margins Return on Equity Return on Assets Annexon N/A -101.19% -75.99% Beam Therapeutics -39.66% -29.00% -22.61%

Does the media favor ANNX or BEAM?

In the previous week, Beam Therapeutics had 11 more articles in the media than Annexon. MarketBeat recorded 15 mentions for Beam Therapeutics and 4 mentions for Annexon. Annexon's average media sentiment score of 0.52 beat Beam Therapeutics' score of 0.50 indicating that Annexon is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Annexon 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Beam Therapeutics 5 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor ARQT or ANNX?

In the previous week, Arcutis Biotherapeutics had 7 more articles in the media than Annexon. MarketBeat recorded 11 mentions for Arcutis Biotherapeutics and 4 mentions for Annexon. Arcutis Biotherapeutics' average media sentiment score of 0.68 beat Annexon's score of 0.52 indicating that Arcutis Biotherapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arcutis Biotherapeutics 3 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Annexon 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Annexon (ANNX) Competitors

$5.63 -0.17 (-2.93%)

Closing price 07/13/2026 04:00 PM Eastern

Extended Trading

$5.60 -0.02 (-0.44%)

As of 04:18 AM Eastern

Compare

ANNX vs. ALMS, CPRX, RCUS, BEAM, and ARQT

Should you buy Annexon stock or one of its competitors? MarketBeat compares Annexon with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Annexon include Alumis (ALMS), Catalyst Pharmaceuticals (CPRX), Arcus Biosciences (RCUS), Beam Therapeutics (BEAM), and Arcutis Biotherapeutics (ARQT). These companies are all part of the "pharmaceutical products" industry.

How does Annexon compare to Alumis?

Annexon (NASDAQ:ANNX) and Alumis (NASDAQ:ALMS) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, institutional ownership, valuation, dividends, earnings, profitability and media sentiment.

Annexon presently has a consensus target price of $16.00, indicating a potential upside of 184.19%. Alumis has a consensus target price of $40.30, indicating a potential upside of 43.42%. Given Annexon's higher possible upside, equities analysts clearly believe Annexon is more favorable than Alumis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Annexon	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Alumis	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83

Annexon has higher earnings, but lower revenue than Alumis. Alumis is trading at a lower price-to-earnings ratio than Annexon, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Annexon	N/A	N/A	-$206.69M	-$1.22	N/A
Alumis	$24.05M	148.96	-$243.32M	-$1.98	N/A

Annexon has a beta of 1.16, meaning that its share price is 16% more volatile than the broader market. Comparatively, Alumis has a beta of -0.73, meaning that its share price is 173% less volatile than the broader market.

Annexon has a net margin of 0.00% compared to Alumis' net margin of -2,825.70%. Alumis' return on equity of -88.79% beat Annexon's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Annexon	N/A	-101.19%	-75.99%
Alumis	-2,825.70%	-88.79%	-70.72%

In the previous week, Alumis had 2 more articles in the media than Annexon. MarketBeat recorded 6 mentions for Alumis and 4 mentions for Annexon. Annexon's average media sentiment score of 0.52 beat Alumis' score of 0.44 indicating that Annexon is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Annexon	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Alumis	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Annexon and Alumis tied by winning 7 of the 14 factors compared between the two stocks.

How does Annexon compare to Catalyst Pharmaceuticals?

Catalyst Pharmaceuticals (NASDAQ:CPRX) and Annexon (NASDAQ:ANNX) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, risk, profitability, dividends, media sentiment and valuation.

79.2% of Catalyst Pharmaceuticals shares are owned by institutional investors. 10.4% of Catalyst Pharmaceuticals shares are owned by company insiders. Comparatively, 10.3% of Annexon shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Catalyst Pharmaceuticals has higher revenue and earnings than Annexon. Annexon is trading at a lower price-to-earnings ratio than Catalyst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Catalyst Pharmaceuticals	$588.99M	6.54	$214.33M	$1.74	18.09
Annexon	N/A	N/A	-$206.69M	-$1.22	N/A

Catalyst Pharmaceuticals has a net margin of 37.08% compared to Annexon's net margin of 0.00%. Catalyst Pharmaceuticals' return on equity of 35.76% beat Annexon's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Catalyst Pharmaceuticals	37.08%	35.76%	31.31%
Annexon	N/A	-101.19%	-75.99%

In the previous week, Annexon had 1 more articles in the media than Catalyst Pharmaceuticals. MarketBeat recorded 4 mentions for Annexon and 3 mentions for Catalyst Pharmaceuticals. Catalyst Pharmaceuticals' average media sentiment score of 1.49 beat Annexon's score of 0.52 indicating that Catalyst Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Catalyst Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Annexon	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Catalyst Pharmaceuticals presently has a consensus price target of $32.00, indicating a potential upside of 1.65%. Annexon has a consensus price target of $16.00, indicating a potential upside of 184.19%. Given Annexon's higher possible upside, analysts plainly believe Annexon is more favorable than Catalyst Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Catalyst Pharmaceuticals	0 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	2 Strong Buy rating(s)	2.56
Annexon	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Catalyst Pharmaceuticals has a beta of 0.74, meaning that its share price is 26% less volatile than the broader market. Comparatively, Annexon has a beta of 1.16, meaning that its share price is 16% more volatile than the broader market.

Summary

Catalyst Pharmaceuticals beats Annexon on 12 of the 16 factors compared between the two stocks.

How does Annexon compare to Arcus Biosciences?

Annexon (NASDAQ:ANNX) and Arcus Biosciences (NYSE:RCUS) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, analyst recommendations, valuation, profitability, risk, institutional ownership and media sentiment.

Annexon has a beta of 1.16, suggesting that its share price is 16% more volatile than the broader market. Comparatively, Arcus Biosciences has a beta of 0.8, suggesting that its share price is 20% less volatile than the broader market.

In the previous week, Arcus Biosciences had 5 more articles in the media than Annexon. MarketBeat recorded 9 mentions for Arcus Biosciences and 4 mentions for Annexon. Arcus Biosciences' average media sentiment score of 1.15 beat Annexon's score of 0.52 indicating that Arcus Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Annexon	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Arcus Biosciences	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Annexon has a net margin of 0.00% compared to Arcus Biosciences' net margin of -156.36%. Arcus Biosciences' return on equity of -68.97% beat Annexon's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Annexon	N/A	-101.19%	-75.99%
Arcus Biosciences	-156.36%	-68.97%	-35.27%

92.9% of Arcus Biosciences shares are owned by institutional investors. 10.3% of Annexon shares are owned by company insiders. Comparatively, 9.6% of Arcus Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Annexon has higher earnings, but lower revenue than Arcus Biosciences. Arcus Biosciences is trading at a lower price-to-earnings ratio than Annexon, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Annexon	N/A	N/A	-$206.69M	-$1.22	N/A
Arcus Biosciences	$247M	14.32	-$353M	-$3.18	N/A

Annexon presently has a consensus target price of $16.00, suggesting a potential upside of 184.19%. Arcus Biosciences has a consensus target price of $35.10, suggesting a potential upside of 24.80%. Given Annexon's higher probable upside, equities analysts plainly believe Annexon is more favorable than Arcus Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Annexon	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Arcus Biosciences	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.58

Summary

Arcus Biosciences beats Annexon on 8 of the 15 factors compared between the two stocks.

How does Annexon compare to Beam Therapeutics?

Annexon (NASDAQ:ANNX) and Beam Therapeutics (NASDAQ:BEAM) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, media sentiment, analyst recommendations, profitability, risk, valuation, institutional ownership and dividends.

Annexon has a beta of 1.16, suggesting that its share price is 16% more volatile than the broader market. Comparatively, Beam Therapeutics has a beta of 2.18, suggesting that its share price is 118% more volatile than the broader market.

Annexon currently has a consensus price target of $16.00, suggesting a potential upside of 184.19%. Beam Therapeutics has a consensus price target of $46.85, suggesting a potential upside of 51.12%. Given Annexon's higher possible upside, equities research analysts clearly believe Annexon is more favorable than Beam Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Annexon	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Beam Therapeutics	1 Sell rating(s)	3 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.73

Beam Therapeutics has higher revenue and earnings than Annexon. Beam Therapeutics is trading at a lower price-to-earnings ratio than Annexon, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Annexon	N/A	N/A	-$206.69M	-$1.22	N/A
Beam Therapeutics	$139.74M	22.82	-$79.99M	-$0.68	N/A

99.7% of Beam Therapeutics shares are owned by institutional investors. 10.3% of Annexon shares are owned by insiders. Comparatively, 3.8% of Beam Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Beam Therapeutics had 11 more articles in the media than Annexon. MarketBeat recorded 15 mentions for Beam Therapeutics and 4 mentions for Annexon. Annexon's average media sentiment score of 0.52 beat Beam Therapeutics' score of 0.50 indicating that Annexon is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Annexon	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Beam Therapeutics	5 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Annexon has a net margin of 0.00% compared to Beam Therapeutics' net margin of -39.66%. Beam Therapeutics' return on equity of -29.00% beat Annexon's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Annexon	N/A	-101.19%	-75.99%
Beam Therapeutics	-39.66%	-29.00%	-22.61%

Summary

Beam Therapeutics beats Annexon on 11 of the 16 factors compared between the two stocks.

How does Annexon compare to Arcutis Biotherapeutics?

Arcutis Biotherapeutics (NASDAQ:ARQT) and Annexon (NASDAQ:ANNX) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, dividends, risk, profitability, institutional ownership and media sentiment.

Arcutis Biotherapeutics has a beta of 1.48, indicating that its stock price is 48% more volatile than the broader market. Comparatively, Annexon has a beta of 1.16, indicating that its stock price is 16% more volatile than the broader market.

Arcutis Biotherapeutics currently has a consensus target price of $34.00, suggesting a potential upside of 25.37%. Annexon has a consensus target price of $16.00, suggesting a potential upside of 184.19%. Given Annexon's higher probable upside, analysts plainly believe Annexon is more favorable than Arcutis Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcutis Biotherapeutics	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50
Annexon	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

In the previous week, Arcutis Biotherapeutics had 7 more articles in the media than Annexon. MarketBeat recorded 11 mentions for Arcutis Biotherapeutics and 4 mentions for Annexon. Arcutis Biotherapeutics' average media sentiment score of 0.68 beat Annexon's score of 0.52 indicating that Arcutis Biotherapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arcutis Biotherapeutics	3 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Annexon	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Annexon has a net margin of 0.00% compared to Arcutis Biotherapeutics' net margin of -0.57%. Arcutis Biotherapeutics' return on equity of -1.41% beat Annexon's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arcutis Biotherapeutics	-0.57%	-1.41%	-0.59%
Annexon	N/A	-101.19%	-75.99%

Arcutis Biotherapeutics has higher revenue and earnings than Annexon. Arcutis Biotherapeutics is trading at a lower price-to-earnings ratio than Annexon, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcutis Biotherapeutics	$376.07M	9.02	-$16.14M	-$0.03	N/A
Annexon	N/A	N/A	-$206.69M	-$1.22	N/A

Summary

Arcutis Biotherapeutics beats Annexon on 10 of the 13 factors compared between the two stocks.

Get Annexon News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ANNX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ANNX vs. The Competition

Export

Metric	Annexon	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$950.29M	$3.71B	$7.05B	$12.61B
Dividend Yield	N/A	2.20%	2.68%	8.00%
P/E Ratio	-4.61	20.85	27.11	24.26
Price / Sales	N/A	314.01	589.96	117.88
Price / Cash	N/A	61.98	29.22	49.36
Price / Book	3.96	8.49	10.74	6.29
Net Income	-$206.69M	$23.83M	$3.58B	$330.66M
7 Day Performance	-12.44%	-3.56%	-2.11%	-1.35%
1 Month Performance	19.53%	6.31%	3.27%	-0.64%
1 Year Performance	115.71%	48.30%	26.31%	19.08%

Annexon Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ANNX Annexon	3.3566 of 5 stars	$5.63 -2.9%	$16.00 +184.2%	+118.2%	$950.29M	N/A	N/A	60	Analyst Downgrade
ALMS Alumis	3.1091 of 5 stars	$30.30 +1.9%	$40.30 +33.0%	+698.3%	$3.86B	$8.40M	N/A	N/A
CPRX Catalyst Pharmaceuticals	3.8771 of 5 stars	$31.47 flat	$32.00 +1.7%	+44.3%	$3.85B	$588.99M	18.09	80	Positive News
RCUS Arcus Biosciences	3.891 of 5 stars	$30.03 -0.8%	$35.10 +16.9%	+200.8%	$3.78B	$236M	N/A	500	News Coverage Positive News Insider Trade Gap Down
BEAM Beam Therapeutics	3.3747 of 5 stars	$35.82 -2.9%	$46.85 +30.8%	+46.5%	$3.69B	$164.01M	N/A	510	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ANNX) was last updated on 7/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Annexon (ANNX) Competitors

ANNX vs. ALMS, CPRX, RCUS, BEAM, and ARQT

How does Annexon compare to Alumis?

Summary

How does Annexon compare to Catalyst Pharmaceuticals?

Summary

How does Annexon compare to Arcus Biosciences?

Summary

How does Annexon compare to Beam Therapeutics?

Summary

How does Annexon compare to Arcutis Biotherapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANNX vs. The Competition

Annexon Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Annexon (ANNX) Competitors

ANNX vs. ALMS, CPRX, RCUS, BEAM, and ARQT

How does Annexon compare to Alumis?

Do analysts prefer ANNX or ALMS?

Which has higher valuation and earnings, ANNX or ALMS?

Which has more volatility and risk, ANNX or ALMS?

Is ANNX or ALMS more profitable?

Does the media prefer ANNX or ALMS?

Summary

How does Annexon compare to Catalyst Pharmaceuticals?

Do insiders and institutionals have more ownership in CPRX or ANNX?

Which has stronger valuation and earnings, CPRX or ANNX?

Is CPRX or ANNX more profitable?

Does the media refer more to CPRX or ANNX?

Do analysts recommend CPRX or ANNX?

Which has more volatility & risk, CPRX or ANNX?

Summary

How does Annexon compare to Arcus Biosciences?

Which has more risk and volatility, ANNX or RCUS?

Does the media favor ANNX or RCUS?

Is ANNX or RCUS more profitable?

Do institutionals & insiders hold more shares of ANNX or RCUS?

Which has preferable earnings & valuation, ANNX or RCUS?

Do analysts recommend ANNX or RCUS?

Summary

How does Annexon compare to Beam Therapeutics?

Which has more volatility and risk, ANNX or BEAM?

Do analysts recommend ANNX or BEAM?

Which has stronger earnings and valuation, ANNX or BEAM?

Do institutionals and insiders hold more shares of ANNX or BEAM?

Does the media favor ANNX or BEAM?

Is ANNX or BEAM more profitable?

Summary

How does Annexon compare to Arcutis Biotherapeutics?

Which has more risk and volatility, ARQT or ANNX?

Do analysts recommend ARQT or ANNX?

Does the media favor ARQT or ANNX?

Is ARQT or ANNX more profitable?

Which has better valuation and earnings, ARQT or ANNX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANNX vs. The Competition

Annexon Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools